Assessing Alnylam Pharmaceuticals (ALNY) Valuation After Mixed Share Performance And Strong AMVUTTRA Uptake
Alnylam Pharmaceuticals (ALNY) has seen mixed share performance recently, but its new drug AMVUTTRA is experiencing strong uptake, leading to a narrative that the stock is 40% undervalued with a fair value of $491.92, despite its current price of $297.45. While growth assumptions are ambitious, the company's P/E ratio of 73.8x is significantly higher than the industry average, indicating potential valuation risk. Investors are encouraged to review the underlying data and consider both upside and warning signs before making investment decisions.
Director Peter Kellogg granted RSUs and stock options at Alnylam (NASDAQ: ALNY)
Alnylam director Peter N. Kellogg received 671 restricted stock units (RSUs) and 1,441 stock options with an exercise price of $298.48 per share. These equity awards, granted on May 20, 2026, will vest in full on the earlier of the first anniversary of the grant date or an earlier qualifying retirement/resignation. Following this transaction, Kellogg directly holds 1,446 common shares and 1,441 stock options in Alnylam Pharmaceuticals, Inc.
Alnylam (NASDAQ: ALNY) awards RSUs and options to board director
Alnylam Pharmaceuticals (NASDAQ: ALNY) director Amy W. Schulman received equity compensation, including 838 restricted stock units (RSUs) and stock options for 1,802 shares. Both awards fully vest on the earlier of the first anniversary of the May 20, 2026 grant date or a qualifying retirement/resignation occurring within 90 days prior to that anniversary. These grants are compensation awards, not open-market trades, and increase her direct common stock holdings to 24,049 shares.
Discipline and Rules-Based Execution in ALNY Response
Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY) shows a mixed sentiment with a mid-channel oscillation pattern. The article highlights an exceptional 91.1:1 risk-reward setup, targeting a 26.5% gain versus 0.3% risk. It also outlines three distinct AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—tailored for different risk profiles and holding periods, alongside a multi-timeframe signal analysis.
Alnylam Q1 Earnings Beat Estimates, Amvuttra Sales Drive Y/Y Growth
Alnylam Pharmaceuticals (ALNY) reported first-quarter 2026 adjusted earnings and revenues that surpassed Zacks Consensus Estimates, primarily driven by strong sales of its lead drug, Amvuttra. The company's total revenues increased by 96% year-over-year, largely due to Amvuttra's label expansion and increased patient demand, alongside contributions from Givlaari and Oxlumo. Alnylam reaffirmed its 2026 financial guidance, anticipating significant year-over-year growth in net product revenues.
How HELIOS-B Phase 3 Vutrisiran Data and Real-World Evidence Expansion Will Impact Alnylam (ALNY) Investors
Alnylam Pharmaceuticals recently reported positive HELIOS-B Phase 3 data for vutrisiran, demonstrating durable transthyretin knockdown and consistent clinical benefits for high-risk ATTR-CM patients, alongside launching the DemonsTTRate real-world study. This strengthens the clinical case for vutrisiran within Alnylam's TTR franchise, which continues to drive strong financials, with Q1 2026 revenues of US$1.17 billion and a reiterated 2026 guidance of US$4.4-4.7 billion from TTR products. While these developments bolster the investment narrative around the TTR portfolio's durability, investors should remain mindful of potential pricing pressures on AMVUTTRA.
Alnylam Issues 2025 Corporate Responsibility Report
Alnylam Pharmaceuticals has released its 2025 Corporate Responsibility Report, highlighting expanded global patient access, increased philanthropic investments, and the establishment of a greenhouse gas emissions reduction framework through 2030. The report emphasizes the company's commitment to delivering life-changing medicines while operating with integrity and accountability, guided by six interconnected pillars including Patients, Science, and Environment & Operations. This demonstrates Alnylam's dedication to integrating corporate responsibility with its business growth and strategic goals.
ALNY Initiated Coverage by Citigroup -- Price Target Set at $380
Citigroup has initiated coverage on Alnylam Pharmaceuticals (ALNY) with a 'Buy' rating and a price target of $380, indicating confidence in the company's growth and RNA interference therapeutics. GuruFocus estimates ALNY is currently undervalued by 41.2%, with a GF Value of $496.81 against its current price of $292.17. Despite insider selling of $11.8 million over the last three months, the company holds a strong GF Score of 75/100, driven by its growth potential.
Alnylam commits $2M to frontline care navigators in Boston
Alnylam Pharmaceuticals, Inc. has published its 2025 Corporate Responsibility Report, outlining its expanded efforts in sustainability and patient access, including a new 2030 greenhouse gas emissions reduction framework. The report highlights a significant $2 million philanthropic investment over two years to support frontline Care Navigators in underserved Boston communities, partnering with institutions like Boston Children’s Hospital and Boston Medical Center. These initiatives reflect Alnylam's commitment to delivering life-changing medicines while operating with integrity and accountability.
How HELIOS-B Phase 3 Vutrisiran Data and Real-World Evidence Expansion Will Impact Alnylam (ALNY) Investors
Alnylam Pharmaceuticals recently released strong HELIOS-B Phase 3 data for vutrisiran, demonstrating durable clinical benefits and low side effects in high-risk ATTR-CM patients. Coupled with robust Q1 2026 financial results and an expanding real-world evidence base, this solidifies the clinical case for their TTR franchise, although investors should remain aware of potential pricing pressures on AMVUTTRA. The company projects significant revenue and earnings growth by 2028, with some analysts even more optimistic.
Alnylam Pharmaceuticals, Inc. $ALNY Shares Bought by iA Global Asset Management Inc.
iA Global Asset Management Inc. significantly increased its stake in Alnylam Pharmaceuticals (ALNY) by 979.5% in the fourth quarter, owning 17,780 shares worth $7.07 million. This move aligns with a generally positive analyst outlook, featuring a "Moderate Buy" consensus and an average price target of $471.96. The company recently exceeded earnings expectations, reporting a $1.99 EPS against $0.87 expected, with revenues up 96.4% year over year.
Alnylam Pharmaceuticals, Inc. $ALNY Position Reduced by DNB Asset Management AS
DNB Asset Management AS significantly reduced its stake in Alnylam Pharmaceuticals (NASDAQ:ALNY) by 10.4% in the fourth quarter, selling 3,561 shares and holding 30,707 shares valued at $12.2 million. Despite this reduction, the biopharmaceutical company reported strong quarterly earnings, beating expectations with an EPS of $1.99 and revenue of $1.17 billion, a 96.4% increase year-over-year. Wall Street analysts maintain a "Moderate Buy" rating for ALNY, with a consensus price target of $471.96, though some have slightly lowered their price objectives.
Alnylam Pharmaceuticals, Inc. $ALNY Shares Bought by ANTIPODES PARTNERS Ltd
ANTIPODES PARTNERS Ltd significantly increased its stake in Alnylam Pharmaceuticals (NASDAQ:ALNY) by 49.8% in the fourth quarter, reaching 47,886 shares valued at approximately $19.0 million. This move is part of a broader trend of strong institutional interest, with hedge funds and other institutional investors collectively owning 92.97% of the company's stock. Alnylam recently exceeded analyst expectations with its quarterly results, reporting $1.99 EPS and $1.17 billion in revenue.
Is the options market predicting a spike in Alnylam Pharmaceuticals stock?
This article will examine whether the options market is signaling a potential surge in Alnylam Pharmaceuticals (ALNY) stock. It will delve into recent options trading activity to determine if investors are betting on an upward price movement for the company. The analysis aims to provide insights into market sentiment regarding ALNY's future performance based on options data.
ALNY Financials: Revenue Breakdown, Margins & Competitor Comparison
Alnylam Pharmaceuticals Inc (ALNY) generates significant revenue from its AMVUTTRA product, which accounts for 76.2% of its total sales, alongside other revenue streams like GIVLAARI and OXLUMO. The company demonstrates strong profitability with an 81.91% gross margin, 23.02% operating margin, and 17.65% net margin, further supported by a high Return on Equity of 90.36%. In a competitive landscape, ALNY, with a market capitalization of $38.32B, shows superior gross margins compared to competitors like ZTS and HLN.
Alnylam Pharmaceuticals Adjusts Valuation Grade Amid Strong Financial Performance Indicators
Alnylam Pharmaceuticals has seen its valuation grade improve from fair to attractive due to strong financial indicators like a high P/E ratio, 80.33% ROCE, and 45.14% ROE. The company reported impressive operating cash flow of USD 524.09 million and a net profit of USD 405.83 million in the last quarter, despite a slight decrease in promoter confidence.
A Look At Alnylam Pharmaceuticals (ALNY) Valuation As HELIOS B Data And TTR Guidance Reassure Investors
Alnylam Pharmaceuticals (ALNY) is being re-evaluated by investors following new HELIOS-B Phase 3 data for vutrisiran and reaffirmed TTR franchise revenue guidance. Despite a 26.7% year-to-date share price drop, the company's valuation narrative suggests it is 40.3% undervalued compared to its last close, putting its fair value at $491.92 due to strong uptake of AMVUTTRA and projected double-digit revenue growth. However, its current P/E ratio of 72.8x is significantly higher than the sector average, suggesting high market expectations and potential risks related to reliance on the TTR franchise and pricing pressures.
Alnylam (NASDAQ: ALNY) director exercises 11,250 stock options at $70.20
Alnylam Pharmaceuticals director Amy W. Schulman exercised 11,250 stock options at $70.20 per share on May 13, 2026. These options were set to expire on June 3, 2026. Following this transaction, Schulman directly holds 23,211 common shares, with no remaining options from this grant.
Capital World Investors holds 10.9M Alnylam shares (NASDAQ: ALNY)
Capital World Investors has reported a beneficial ownership of 10,916,799 shares of Alnylam Pharmaceuticals, representing an 8.2% stake in the company. This disclosure was made via an amended Schedule 13G/A SEC filing. The filing details Capital World Investors' sole voting power over 10,871,837 shares and sole dispositive power over all 10,916,799 shares.
Is Alnylam (ALNY) One of the Best Aggressive Growth Stocks to Buy?
H.C. Wainwright reaffirmed its Buy rating on Alnylam Pharmaceuticals (NASDAQ:ALNY) with a $510 price target after the company reported strong Q1 2026 results, showing a 121% year-over-year revenue increase. Although some figures were slightly below analyst expectations, the company maintained its optimistic full-year revenue guidance. Alnylam, a leader in RNAi therapeutics, is well-positioned with $3.0 billion in cash and upcoming catalysts.
Alnylam Pharmaceuticals stock (US02005N1000): Backs TTR revenue outlook amid AMVUTTRA growth
Alnylam Pharmaceuticals has reaffirmed its full-year TTR revenue guidance of $4.4-4.7 billion, despite a Q1 slowdown, attributing growth to AMVUTTRA's expanded access and prescriber base. The company's Q1 TTR revenue reached $910 million, primarily driven by AMVUTTRA, and management anticipates sustained sequential quarterly growth. This positions Alnylam as a key biotech investment, capitalizing on its RNAi therapeutics and strong presence in the ATTR amyloidosis market.
Alnylam Pharmaceuticals Backs TTR Outlook as AMVUTTRA Access, Prescriber Growth Build
Alnylam Pharmaceuticals remains confident in its TTR revenue guidance, despite slower first-quarter sequential growth, driven by growing AMVUTTRA access, international launches, and prescriber expansion. CFO Jeff Poulton noted that the company is transitioning from focusing solely on TTR to broadening its pipeline, with AMVUTTRA sales still playing a crucial role. Alnylam also highlighted nucresiran, a next-generation TTR product with potential for higher operating margins due to lower royalty burdens, and expects several key pipeline readouts in the second half of the year.
New Data Analyses Presented at Heart Failure 2026 Demonstrate Robust and Consistent Clinical Benefit of Vutrisiran as a First-Line Treatment Option Across ATTR-CM Patient Populations, Including Patients with a High Disease Burden
Alnylam Pharmaceuticals announced new analyses from the HELIOS-B Phase 3 study of vutrisiran, presented at Heart Failure 2026, showing consistent clinical benefits for ATTR-CM patients, including those with high disease burden. The data support vutrisiran as a first-line treatment, demonstrating maintained efficacy across various patient subgroups and concomitant therapies. A large pooled safety analysis also confirmed a consistent safety profile with no clinically meaningful ocular effects related to vitamin A lowering.
Alnylam Pharmaceuticals stock (US02005N1000): Q1 earnings beat and vutrisiran data
Alnylam Pharmaceuticals (ALNY) reported stronger-than-expected Q1 2026 earnings, with an EPS of $1.99, significantly beating analyst estimates. The company also presented positive new data from its HELIOS-B study for vutrisiran, highlighting clinical benefits for ATTR-CM patients. These positive developments underscore Alnylam's continued leadership in RNAi therapeutics and its growth potential in the biotech sector.
Heart drug vutrisiran tied to fewer deaths in ATTR-CM
Alnylam Pharmaceuticals announced new analyses from its HELIOS-B Phase 3 study, revealing that the heart drug vutrisiran significantly reduced all-cause mortality and recurrent cardiovascular events in patients with transthyretin-mediated amyloidosis with cardiomyopathy (ATTR-CM). The data, presented at Heart Failure 2026, demonstrated consistent clinical benefits across diverse patient populations, including those with high disease burden and existing comorbidities like atrial fibrillation. Additionally, a pooled safety analysis of over 25,000 patient-years with TTR-silencing RNAi therapies showed a consistent safety profile with low rates of vitamin A deficiency-related ocular adverse events.
How Alnylam’s Swing to Quarterly Profitability Could Reshape the Outlook for Alnylam Pharmaceuticals (ALNY) Investors
Alnylam Pharmaceuticals (ALNY) reported a significant swing to profitability in Q1 2026, with revenue reaching US$1,167.18 million and net income at US$205.99 million, compared to a net loss in the prior year. This shift signals a major change in the company's operating profile, potentially influencing how investors view its RNAi-focused business and its existing narrative around growth, financial risk, and leadership in RNAi therapy. While the move to profit boosts short-term confidence, investors are cautioned to consider ongoing risks such as pricing pressure, royalty obligations, and the need for continued pipeline success, despite the company's projection of significant revenue and earnings growth by 2028.
Behavioral Patterns of ALNY and Institutional Flows
This article analyzes behavioral patterns and institutional flows for Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY). It highlights a neutral near-term sentiment that could moderate mid-term weakness, noting that support is being tested. The analysis provides specific risk-reward setups and outlines three distinct AI-generated trading strategies (Position Trading, Momentum Breakout, and Risk Hedging) tailored for different risk profiles and holding periods, along with multi-timeframe signal analysis.
Is It Time To Reconsider Alnylam Pharmaceuticals (ALNY) After Recent RNAi Progress And Volatile Price Moves
Alnylam Pharmaceuticals (ALNY) has shown volatile price moves recently, with a 4.4% decline over 7 days but a 14.5% gain over 1 year. Simply Wall St's valuation model suggests the stock is currently 52.1% undervalued based on a Discounted Cash Flow (DCF) analysis, with an estimated intrinsic value of $617.37 per share against a market price of $295.91. However, its P/E ratio of 73.44x is significantly higher than both its industry average and its calculated "Fair Ratio" of 29.82x, indicating it is overvalued by this metric.
Is It Time To Reconsider Alnylam Pharmaceuticals (ALNY) After Recent RNAi Progress And Volatile Price Moves
Alnylam Pharmaceuticals (ALNY) has shown volatile price moves but is up significantly over longer periods, driven by RNAi therapies and pipeline developments. While a Discounted Cash Flow (DCF) analysis suggests the stock is 52.1% undervalued, its current P/E ratio of 73.44x is considerably higher than both its industry average and a calculated "Fair Ratio" of 29.82x, indicating it might be overvalued by this metric. Investors can use Simply Wall St's "Narratives" tool to create their own valuation scenarios for ALNY.
Alnylam to Webcast Presentations at Upcoming Investor Conferences - May 7, 2026
Alnylam Pharmaceuticals, a leader in RNAi therapeutics, announced that its management will be presenting company overviews at two upcoming investor conferences. These include the BofA Securities Healthcare Conference on May 13, 2026, and the Goldman Sachs Annual Healthcare Conference on June 9, 2026. Live audio webcasts and replays of these presentations will be available on the Investors section of the Company's website.
FDA’s Untitled Letter tells Alnylam its Amvuttra survival claims don’t quite add up
The FDA's Office of Prescription Drug Promotion (OPDP) issued an Untitled Letter to Alnylam Pharmaceuticals regarding misleading survival claims for its drug Amvuttra on its consumer website. The OPDP found that Alnylam's claims of Amvuttra extending life were based on an open-label extension of a study, lacking a concurrent placebo group, thus making the claims unsubstantiated. Alnylam has 15 working days to respond to the letter and has since altered the headline on its Amvuttra webpage to remove direct longevity claims.
Heart drug vutrisiran shows steady profile in new analyses
Alnylam Pharmaceuticals is presenting new analyses from its Phase 3 HELIOS-B study of vutrisiran, a drug for transthyretin amyloidosis with cardiomyopathy (ATTR-CM), at Heart Failure 2026. The data suggests vutrisiran consistently works across a diverse patient population by reducing transthyretin production. The company is also launching DemonsTTRate, a long-term observational study to track the drug's real-world performance, highlighting a shift towards understanding healthspan and intercepting disease at its molecular root.
Alnylam to Webcast Presentations at Upcoming Investor Conferences
Alnylam Pharmaceuticals announced that its management will present company overviews at two upcoming investor conferences: the BofA Securities Healthcare Conference on May 13, 2026, and the Goldman Sachs Annual Healthcare Conference on June 9, 2026. Live audio webcasts of these presentations will be available on the Investors section of the company's website, with replays accessible within 48 hours after each event. The company, a leader in RNAi therapeutics, continues to focus on developing transformative therapies and expanding its pipeline.
Alnylam to Webcast Presentations at Upcoming Investor Conferences
Alnylam Pharmaceuticals, Inc. announced that its management will present company overviews at two upcoming investor conferences: the BofA Securities Healthcare Conference on May 13, 2026, and the Goldman Sachs Annual Healthcare Conference on June 9, 2026. Live audio webcasts of these presentations will be available on the Investors section of the company’s website, with replays accessible within 48 hours. Alnylam is a leading RNAi therapeutics company focused on developing transformative therapies and has six approved medicines.
FMR LLC amends Schedule 13G to show 14.64M ALNY shares (NASDAQ: ALNY)
FMR LLC has filed an amended Schedule 13G, reporting a beneficial ownership of 14,640,524.87 shares of Alnylam Pharmaceuticals Inc (ALNY) common stock, which represents an 11.0% stake as of March 31, 2026. The filing indicates that FMR LLC holds 14,103,896.98 shares with sole voting power and that the ownership is held on behalf of multiple clients. This update clarifies FMR LLC's holdings and control over ALNY shares.
H.C. Wainwright reiterates Alnylam stock rating on strong TTR sales
H.C. Wainwright maintained a Buy rating and $510 price target for Alnylam Pharmaceuticals (NASDAQ:ALNY) after the company reported strong first-quarter 2026 results, with total net product revenue reaching $1,036 million, up 121% year-over-year. The transthyretin (TTR) franchise was a major contributor, generating $910.4 million, a 153% year-over-year increase. Alnylam reaffirmed its full-year 2026 guidance, demonstrating strong performance and future growth prospects despite its stock trading above its fair value.
H.C. Wainwright Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $510
H.C. Wainwright has reiterated its Buy rating for Alnylam Pharmaceuticals (ALNY.US), maintaining a target price of $510. This indicates a continued positive outlook from the analyst firm on the company's stock performance and potential.
Research Alert: CFRA Maintains Hold Opinion On Shares Of Alnylam Pharmaceuticals, Inc
CFRA has reiterated its "Hold" opinion on shares of Alnylam Pharmaceuticals, Inc. This indicates that CFRA advises investors to maintain their current position in Alnylam stock. The research alert signifies a continued neutral stance from the analyst firm regarding the company's valuation or future prospects.
Alnylam Pharmaceuticals (ALNY) Valuation After Q1 2026 Profit Breakthrough And Revenue Surge
Alnylam Pharmaceuticals (ALNY) reported a significant Q1 2026 profit breakthrough and revenue surge, with net product revenues exceeding US$1 billion and a 121% year-over-year increase. Despite a 51% discount to the average analyst price target and a "39.4% Undervalued" narrative, the company's current P/E of 73.9x is significantly higher than the industry average, pointing to potential valuation risk. Investors are encouraged to consider the full picture, including key rewards and warning signs, before making investment decisions.
Alnylam Pharmaceuticals (ALNY) Valuation After Q1 2026 Profit Breakthrough And Revenue Surge
Alnylam Pharmaceuticals (ALNY) reported a significant shift to net profit in Q1 2026 with combined net product revenues exceeding US$1 billion, marking a 121% year-over-year increase. Despite recent strong results, the company's shorter-term share price performance has been negative, though its 5-year return is robust. The article explores whether Alnylam, currently trading at a discount to analyst targets, still presents a significant opportunity, highlighting its "undervalued" narrative balanced against valuation risks indicated by a high P/E ratio.
Alnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran in ATTR-CM
Alnylam Pharmaceuticals announced it will present new data analyses for vutrisiran at Heart Failure 2026. These analyses from the Phase 3 HELIOS-B study further support vutrisiran, a TTR silencer, as a first-line treatment for patients with ATTR-CM, characterizing its clinical profile and safety across various patient subgroups and concomitant therapies. The presentations will include pharmacodynamic and safety analyses, alongside the design of a new observational study called DemonsTTRate.
Should Alnylam’s Billion‑Dollar Quarter and Return to Profitability Require Action From Alnylam Pharmaceuticals (ALNY) Investors?
Alnylam Pharmaceuticals reported a strong first quarter in 2026, achieving over US$1 billion in combined net product revenue and turning a previous net loss into a US$205.99 million net profit. This performance was driven by its TTR franchise and AMVUTTRA uptake, reinforcing confidence in its near-term growth, though revenue concentration remains a key risk. The company has reiterated its full-year guidance and continues to invest in late-stage RNAi programs, with analysts projecting significant future revenue and earnings growth.
Should Alnylam’s Billion‑Dollar Quarter and Return to Profitability Require Action From Alnylam Pharmaceuticals (ALNY) Investors?
Alnylam Pharmaceuticals reported a strong first quarter in 2026 with revenue exceeding $1 billion and a return to profitability, driven by its TTR franchise and AMVUTTRA. This performance reinforces near-term confidence in the company's RNAi platform and TTR-driven strategy, but investors should still consider the risk of revenue concentration in the TTR portfolio. The company reiterated its full-year guidance and is expanding late-stage TTR therapy development, which could diversify its future revenue streams.
Hussman Strategic Advisors Inc. Buys Shares of 6,300 Alnylam Pharmaceuticals, Inc. $ALNY
Hussman Strategic Advisors Inc. initiated a new position in Alnylam Pharmaceuticals (NASDAQ:ALNY) during the fourth quarter, acquiring 6,300 shares valued at approximately $2.505 million. This investment comes as Alnylam reported strong Q1 results, exceeding EPS and revenue expectations with a significant surge in Amvuttra sales. Despite a "Moderate Buy" consensus from analysts, the company has seen insider share sales totaling $12.37 million in the last 90 days.
Alnylam Pharmaceuticals, Inc. $ALNY Shares Sold by Kornitzer Capital Management Inc. KS
Kornitzer Capital Management Inc. KS significantly reduced its stake in Alnylam Pharmaceuticals (NASDAQ:ALNY) by 53.1% in the fourth quarter, selling 12,575 shares and retaining 11,114 shares valued at $4.42 million. This comes as Alnylam Pharmaceuticals reported strong Q1 results, beating EPS and revenue estimates, driven by a 96% year-over-year revenue growth and substantial Amvuttra sales. Despite mixed analyst target adjustments, the company maintains a "Moderate Buy" rating, with institutional investors and hedge funds owning nearly 93% of the stock.
Raymond James Reaffirms Their Hold Rating on Alnylam Pharma (ALNY)
Raymond James analyst Tiago Fauth has maintained a Hold rating on Alnylam Pharma (ALNY) with a price target of $377.00. This comes despite Alnylam Pharma reporting strong quarterly revenue of $1.1 billion and a net profit of $186.42 million. Insider sentiment is currently negative, with increased selling of shares by corporate insiders, including the CEO in March 2026.
A Quick Look at Today's Ratings for Alnylam Pharmaceuticals(ALNY.US), With a Forecast Between $377 to $527
This article provides an overview of recent analyst ratings for Alnylam Pharmaceuticals (ALNY.US). It details the latest ratings and price targets from five analysts, with a general consensus that the company is a "Buy" or "Outperform." The target prices range from $377 to $527, reflecting varied expectations but overall positive sentiment.
Wells Fargo & Company Issues Positive Forecast for Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock Price
Wells Fargo & Company increased its price target for Alnylam Pharmaceuticals (NASDAQ:ALNY) from $376 to $377, maintaining an "equal weight" rating, suggesting a 24.67% upside. This follows Alnylam's strong Q1 results, which significantly beat analyst expectations with $1.17 billion in revenue and $1.99 EPS, reflecting 96% year-over-year revenue growth. Despite generally positive analyst sentiment (Moderate Buy consensus), recent insider selling and an external report flagging high risk of losses introduce potential volatility.
RBC Trims Price Target on Alnylam Pharmaceuticals to $445 From $450, Keeps Outperform Rating
RBC has adjusted its price target for Alnylam Pharmaceuticals (ALNY) to $445 from $450, while maintaining an "Outperform" rating on the stock. This update follows Alnylam Pharmaceuticals' recent first-quarter earnings report for the period ending March 31, 2026. The biopharmaceutical company reported rising adjusted net income and revenue in Q1, and reiterated its product revenue guidance for 2026.
Alnylam Pharmaceuticals Backs 2026 Views >ALNY
Alnylam Pharmaceuticals (ALNY) has reaffirmed its financial guidance for 2026. The company continues to anticipate total product revenues between $3.4 billion and $4.0 billion for that year. This reiteration suggests confidence in its long-term growth prospects and pipeline performance.
